Merck & Co., Inc. (MRK.MX)
Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
At close: 01:44PM CST
| Previous close | 2,200.00 |
| Open | 2,200.00 |
| Bid | 2,000.11 x 49400 |
| Ask | 2,200.00 x 13500 |
| Day's range | 2,200.00 - 2,200.00 |
| 52-week range | 1,725.90 - 2,252.70 |
| Volume | |
| Avg. volume | 1,532 |
| Market cap | 5.582T |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 144.93 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 51.09 (2.32%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Business Wire
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
RAHWAY, N.J., May 09, 2024--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial
- Business Wire
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
RAHWAY, N.J., May 08, 2024--Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
- Business Wire
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
© 2024 Yahoo. All rights reserved.